U.S. License Holder:
Immunomedics Inc.
Date of License:
April-22-2020
Last Update:
May-15-2022
FDA-Approved Indications
TRODELVY (sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.